A randomized, double-blind, placebo-controlled pilot study of simvastatin in aneurysmal subarachnoid hemorrhage

Sherry H.Y. Chou, Eric E. Smith, Neeraj Badjatia, Raul G. Nogueira, John R. Sims, Christopher S. Ogilvy, Guy A. Rordorf, Cenk Ayata*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

119 Scopus citations

Abstract

Background and Purpose: Studies suggest statins ameliorate aneurysmal subarachnoid hemorrhage (SAH)-induced cerebral vasospasm and ischemic complications. We tested safety and feasibility of simvastatin 80 mg/d for vasospasm prevention in SAH patients. Methods: Thirty-nine statin-naïve Fisher grade 3 SAH subjects were double-blind randomized to receive simvastatin 80 mg/d (n≤19) or placebo (n≤20), stratified by Hunt and Hess grade. Primary end points were death and drug morbidity. Results: Mortality was 3/20 in the placebo and 0/19 in the simvastatin group. Study drug was withdrawn in 1 subject in each treatment group for reversible liver enzyme or creatine phosphokinase elevation. Angiographically-confirmed vasospasm occurred in 8/20 placebo and 5/19 simvastatin-treated subjects. Vasospasm-related ischemic infarcts developed in 5/20 placebo and 2/19 simvastatin-treated subjects. Conclusion: Simvastatin for the prevention of delayed cerebral ischemia is safe and feasible after SAH. A larger study is needed to test its efficacy.

Original languageEnglish (US)
Pages (from-to)2891-2893
Number of pages3
JournalStroke
Volume39
Issue number10
DOIs
StatePublished - Oct 1 2008
Externally publishedYes

Keywords

  • Clinical trial
  • Delayed cerebral ischemia
  • Vasospasm

ASJC Scopus subject areas

  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine
  • Advanced and Specialized Nursing

Fingerprint

Dive into the research topics of 'A randomized, double-blind, placebo-controlled pilot study of simvastatin in aneurysmal subarachnoid hemorrhage'. Together they form a unique fingerprint.

Cite this